1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Kobo Biotech Ltd.

Kobo Biotech Ltd.

KOBO.BO
Kobo Biotech Ltd.IN flagBombay Stock Exchange
8.58
INR
+0.14
- -
204.42MMarket Cap
Kobo Biotech Ltd.
KOBO.BO
(Bombay Stock Exchange)

Recent

price

8.58

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
55.7
66.87
72.05
127.71
179.4
25.28
12.92
13.72
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
2.48
3.96
4.37
6.72
6.22
-13.99
-13.45
-6.94
-8.07
-10.04
-10.27
-8.82
-8.07
-6.39
-2.33
-2.07
-2.12
Basic EPS, GAAP
-4.7
7.38
-1.01
21.98
12.83
2.81
8.59
- -
13.55
13.21
8.79
6.08
1.05
39.35
0.37
0.09
- -
Free Cash Flow per Basic Share
- -
- -
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
10
10
10
10
10
0.48
-13.25
-18.99
-26.92
-36.98
-47.27
-56.09
-64.14
-70.53
-72.83
10.01
- -
Book Value per Share
21.29
24.08
27.29
33.63
39.06
19.81
6.08
2.71
-7.79
-17.84
-28.12
-36.94
-45
-51.39
-53.7
-55.82
- -
Tangible Book Value per Share
22
22
22
22
22
22
22
24
24
24
24
24
24
24
24
24
24
Basic Weighted Avg Shares
1,253
1,505
1,621
2,873
4,037
569
291
325
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
12.45
13.69
-93.93
13.32
8.16
-29.13
-60.94
-10.54
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
55
59
61
109
100
96
78
73
68
64
61
59
56
46
41
41
41
Depreciation Expense
56
89
98
151
140
-315
-303
-165
-192
-239
-245
-210
-192
-152
-56
-49
-50
Net Income, GAAP
- -
- -
- -
6.95
8.11
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
4.45
5.92
6.07
5.26
3.47
-55.35
-104.13
-50.57
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
967
1,098
415
473
445
56
-218
-197
-505
-850
-1,098
-1,249
-1,399
-1,258
-1,281
-1,299
- -
Working Capital
1,142
1,409
693
517
331
760
711
710
584
414
349
349
335
335
327
317
- -
LT Debt
479
542
614
757
879
446
137
64
-186
-425
-670
-880
-1,072
-1,224
-1,280
-1,329
- -
Total Equity
- -
- -
- -
27.59
16.28
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
40.19
10.98
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
24.81
39.56
43.74
67.18
62.19
-266.99
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'24
Jun'25
ST Debt
- -
1,080
- -
LT Borrowings
- -
317
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
24
- -
Market Capitalization
74
91
90

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'24
Jun'25
Total Current Assets
- -
379
- -
Cash, Cash Equivalents & STI
- -
7
- -
Accounts Receivable, Net
- -
120
- -
Inventories
- -
180
- -
Total Current Liabilities
- -
1,678
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,080
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-24.93%
15.16%
3.85%
Free Cash Flow
- -
669.44%
-76.72%
Net Income, GAAP
-12.42%
-23.64%
-11.25%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.62
-0.46
-0.5
- -
-2.33
2024
-0.51
-0.51
-0.52
- -
-2.07
2025
-0.56
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Rimrock Gold Corp. (RMRK)
Kangmei Pharmaceutical Co., Ltd. (600518.SS)
MedAvail Holdings, Inc. (MDVL)
MedAvail Holdings, Inc. (MDVLQ)
Gujarat Themis Biosyn Limited (GUJTHEM.BO)
Beihai Gofar Chuanshan Biological Co., Ltd. (600538.SS)
Business
Kobo Biotech Limited manufactures active pharmaceutical ingredients using fermentation technology at its facility in Solapur, Maharashtra, spread over 21 acres; the company produces pharmaceutical intermediates, including ephedrine and pseudo-ephedrine with an installed capacity of 150 metric tons per annum, as well as agrochemical and pigment intermediates. Incorporated in 1993 and headquartered in Mumbai, India, with a registered office in Hyderabad, Telangana, Kobo Biotech operates primarily in the pharmaceuticals and biotechnology segments, serving domestic and international markets with a focus on bulk drugs and APIs. Formerly known as Avon Lifesciences Limited, the company changed its name in October 2020; it currently faces financial challenges, including ongoing proceedings under the Corporate Insolvency Resolution Process as evidenced by regular Committee of Creditors meetings through 2025 and reported losses, such as a net loss of INR 1.33 crore in the first quarter of fiscal 2025, with operational activities at the Solapur facility at a standstill.